Osi Pharmaceuticals, Inc.

Qinghua Weng

Mark Joseph Mulvihill

Jing Wang

Xin Chen

Andrew Philip Crew

Heather Renee Coate

Bijoy Panicker

Douglas S Werner

Arno G Steinig

Hanqing Dong

Lee Daniel Arnold

An-Hu Li

Meizhong Jin

Ayako Honda

Kristen Michelle Mulvihill

Kam W Siu

James David Beard

Han-Qing Dong

Brian Volk

Paula A R Tavares

Andrew Kleinberg

Apoorba Bharadwaj

Radoslaw Laufer

Dan Maarten Berger

Yingchuan Sun

Kenneth W Foreman

Tao Zhang

Anthony Innocenzo Nigro

Cara Cesario

James G Tarrant

Robin Wilkes

Michael J Wyle

Keith Hornberger

Ramesh C Gupta

Qun-Sheng Ji

Amo G Steinig

Lifu Ma

Lydia Saroglou

Ti Wang

Rajaram Sangem

Andrew-Philip Crew

Lee D Arnoldd

Paula AR Tavares

Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.

Fused bicyclic mTOR inhibitors

Compounds of Formula 1, as shown below and defined herein: 

7-aminofuropyridine derivatives

2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition. 

2-aminopyridine kinase inhibitors

Compounds of the formula  and pharmaceutically acceptable salts thereof, wherein X, X, X, X, X, X, X, R, and Qare defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors

Furo[3,2-c]Pyridine and Thieno[3,2-c]pyridine compounds of Formula I, and pharmaceutically acceptable salts thereof, preparation, intermediates, pharmaceutical compositions, and use, such as in disease treatment, including cancers, including conditions in which EMT is involved, including conditions mediated by protein kinase activity such as RON and/or MET. 

Furo[3,2-C]pyridines

Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X, X, X, and Qare defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

Substituted thienol[2,3-d]pyrimidines as kinase inhibitors

Growing community of inventors

West Islip, NY, United States of America

Qinghua Weng